As distinct populations of myeloma cells have CD19 expression [50], and early reports have shown responses to CD19 targeted CAR T cell therapy with improved PFS in R/R multiple myeloma [51], initial dual targeted approaches focused on combinatorial CD19 and BCMA CARs as a potential strategy improve response and durability. This evidence concerns the gene CD19 and plasma cell myeloma.